Nomura Holdings Inc. Acquires 5,502 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Nomura Holdings Inc. grew its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 218.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 8,022 shares of the specialty pharmaceutical company's stock after acquiring an additional 5,502 shares during the period. Nomura Holdings Inc.'s holdings in Jazz Pharmaceuticals were worth $988,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Nuveen Asset Management LLC raised its stake in shares of Jazz Pharmaceuticals by 1.8% in the fourth quarter. Nuveen Asset Management LLC now owns 468,346 shares of the specialty pharmaceutical company's stock valued at $57,677,000 after acquiring an additional 8,448 shares during the last quarter. McGowan Group Asset Management Inc. bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at about $6,034,000. Mubadala Investment Co PJSC bought a new position in Jazz Pharmaceuticals in the 4th quarter valued at about $2,463,000. Lighthouse Investment Partners LLC bought a new position in shares of Jazz Pharmaceuticals during the fourth quarter worth approximately $3,017,000. Finally, Focus Partners Wealth acquired a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth approximately $551,000. Institutional investors and hedge funds own 89.14% of the company's stock.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,140 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $137.81, for a total transaction of $157,103.40. Following the sale, the chief accounting officer now directly owns 7,012 shares in the company, valued at approximately $966,323.72. The trade was a 13.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 6,500 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $144.25, for a total transaction of $937,625.00. Following the completion of the transaction, the chief executive officer now directly owns 464,058 shares in the company, valued at approximately $66,940,366.50. This trade represents a 1.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 28,236 shares of company stock valued at $3,956,190 in the last ninety days. Corporate insiders own 4.20% of the company's stock.

Analyst Upgrades and Downgrades

JAZZ has been the topic of a number of recent research reports. Morgan Stanley cut their price target on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. Royal Bank of Canada decreased their price target on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. JPMorgan Chase & Co. lifted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. UBS Group upgraded shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $145.00 to $179.00 in a report on Friday, March 7th. Finally, Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and boosted their price target for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $182.79.

Jazz Pharmaceuticals Trading Up 0.2%

Shares of NASDAQ:JAZZ traded up $0.25 during midday trading on Friday, reaching $108.07. 958,795 shares of the company's stock were exchanged, compared to its average volume of 851,979. Jazz Pharmaceuticals plc has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The firm's 50 day simple moving average is $112.87 and its two-hundred day simple moving average is $121.97. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a market cap of $6.66 billion, a price-to-earnings ratio of 15.22, a P/E/G ratio of 1.04 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing the consensus estimate of $4.65 by ($2.97). The business had revenue of $897.84 million during the quarter, compared to analysts' expectations of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. Jazz Pharmaceuticals's quarterly revenue was down .5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.68 earnings per share. As a group, sell-side analysts forecast that Jazz Pharmaceuticals plc will post 16.96 EPS for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.